During the last session, Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s traded shares were 34.11 million, with the beta value of the company hitting 0.90. At the end of the trading day, the stock’s price was $5.59, reflecting an intraday gain of 4.29% or $0.23. The 52-week high for the RXRX share is $12.36, that puts it down -121.11 from that peak though still a striking 32.2% gain since the share price plummeted to a 52-week low of $3.79. The company’s market capitalization is $2.27B, and the average intraday trading volume over the past 10 days was 31.17 million shares, and the average trade volume was 26.14 million shares over the past three months.
Recursion Pharmaceuticals Inc (RXRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.50. RXRX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.35.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Recursion Pharmaceuticals Inc (RXRX) registered a 4.29% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.29% in intraday trading to $5.59, hitting a weekly high. The stock’s 5-day price performance is 8.97%, and it has moved by 1.82% in 30 days. Based on these gigs, the overall price performance for the year is -17.31%. The short interest in Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is 120.08 million shares and it means that shorts have 4.45 day(s) to cover.
The consensus price target of analysts on Wall Street is $6, which implies an increase of 6.83% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6 and $6 respectively. As a result, RXRX is trading at a discount of -7.33% off the target high and -7.33% off the low.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
In the rating firms’ projections, revenue will increase 20.63% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 16.23M as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 20.03M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 14.42M and 26.08M respectively. In this case, analysts expect current quarter sales to grow by 12.60% and then drop by -23.19% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -35.28%. While earnings are projected to return 13.80% in 2025, the next five years will return 25.10% per annum.
RXRX Dividends
Recursion Pharmaceuticals Inc is due to release its next quarterly earnings on 2025-May-05. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders
Recursion Pharmaceuticals Inc insiders own 5.10% of total outstanding shares while institutional holders control 74.16%, with the float percentage being 78.15%. ARK INVESTMENT MANAGEMENT LLC is the largest shareholder of the company, while 439.0 institutions own stock in it. As of 2024-06-30, the company held over 28.14 million shares (or 11.6199% of all shares), a total value of $211.07 million in shares.
The next largest institutional holding, with 26.59 million shares, is of BAILLIE GIFFORD & CO’s that is approximately 10.9787% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $199.42 million.
Also, the Mutual Funds coming in first place with the largest holdings of Recursion Pharmaceuticals Inc (RXRX) shares are ARK ETF Trust-ARK Innovation ETF and ARK ETF Trust-ARK Genomic Revolution ETF . Data provided on May 31, 2025 indicates that ARK ETF Trust-ARK Innovation ETF owns about 18.3 shares. This amounts to just over 4.58 percent of the company’s overall shares, with a $102.29 million market value. The same data shows that the other fund manager holds slightly less at 11.26, or about 2.82% of the stock, which is worth about $62.95 million.
